Who
Richard A. Mark
Director
Company insider
Files Form 4 as: Director, Viatris; Director, Goldman Sachs Middle Market Lending Corp. II; Director, Goldman Sachs Private Credit; Director, Mylan II B.V; Director, Goldman Sachs Middle Market Lending; Director, Goldman Sachs BDC; Director, Katy Industries.
In numbers
- Trades disclosed
- 89
- Buys
- 31
- Sells
- 0
- Bought
- $608K
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 26 May 2016
- Last trade
- 6 Mar 2026
- Last filed
- 10 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,175 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,174.49 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,174.492 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,175 at $0.00 | filing |
| 14 Oct 2025filed 16 Oct 2025 | Goldman Sachs Middle Market Lending Corp. II | SEC FORM 4 Code D | —10,914.89 | filing |
| 6 Mar 2025filed 10 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —23,660 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —18,204 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —772.84 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —18,204 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —773 at $0.00 | filing |
| 9 Jul 2024filed 1 Aug 2024 | Goldman Sachs Middle Market Lending Corp. II | SEC FORM 4 Bought | $25K1,304.36 at $19.17 | filing |
| 9 Jul 2024filed 11 Jul 2024 | Goldman Sachs Middle Market Lending Corp. II | SEC FORM 4 Bought | —0 | filing |
| 6 May 2024filed 21 May 2024 | Goldman Sachs Middle Market Lending Corp. II | SEC FORM 4 Bought | $37K1,992.41 at $18.82 | filing |
| 6 May 2024filed 8 May 2024 | Goldman Sachs Middle Market Lending Corp. II | SEC FORM 4 Bought | —0 | filing |
News
No headline names them, or the companies they trade most, lately.